Designation of Ivacaftor (Kalydeco) as an Orphan Drug - Vertex Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring their quality, safety, and efficacy. This Act provides the legislative framework under which the Therapeutic Goods Administration operates, with the overarching aim of protecting public health by controlling the supply of therapeutic goods. The 1989 Act introduced a structured approach to the regulation of therapeutic goods, addressing gaps in the existing regulatory environment by establishing a comprehensive system for the evaluation, registration, and monitoring of therapeutic products available in Australia. The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to address the need for a robust regulatory framework governing therapeutic goods. The policy objective was to ensure that therapeutic goods are safe, of acceptable quality, and their benefits outweigh any risks, thereby protecting public health. The designation of Ivacaftor (KALYDECO) as an orphan drug under the Therapeutic Goods Regulations 1990 exemplifies the Act's role in facilitating access to treatments for rare conditions, such as cystic fibrosis in patients with specific genetic mutations. This specific designation, made by the Delegate of the Secretary on 14 August 2014, highlights the Act's aim to support the development and availability of treatments for underserved medical needs.

Scope and Application

The Therapeutic Goods Act 1989, as amended and governed by the Therapeutic Goods Administration (TGA) within the Commonwealth of Australia, designates specific therapeutic goods including medicines, medical devices, and blood products. In this instance, the Act applies to the designation of Ivacaftor (KALYDECO) as an orphan drug for the treatment of cystic fibrosis (CF) in patients who have a specific genetic mutation in the CFTR gene. The Act specifically targets entities and persons involved in the sponsorship, registration, and supply of therapeutic goods within Australia, including pharmaceutical companies like Vertex Pharmaceuticals Australia Pty Ltd, which is the sponsor of Ivacaftor (KALYDECO) in this context. The geographic reach of this legislation is national, as the TGA operates under the Australian Commonwealth government. The Act does not specify any exclusions or exemptions for orphan drug designation but relies on the Therapeutic Goods Regulations 1990 for further detailing and procedural requirements. These regulations can extend or restrict the application of the Act through subordinate instruments, ensuring comprehensive governance of therapeutic goods within Australia.

Key Provisions

The Therapeutic Goods Act 1989, through the Therapeutic Goods Regulations 1990, allows for the designation of certain drugs as orphan drugs, which are medications intended for the treatment of rare medical conditions. In this instance, Ivacaftor (KALYDECO) has been designated as an orphan drug (Section 16J(2) of the Regulations) for the treatment of cystic fibrosis (CF) in patients with specific genetic mutations. This particular designation was made on 14 August 2014 by Dr Anthony Gill, the Delegate of the Secretary, and concerns the use of Ivacaftor (KALYDECO) in tablet form for patients with a CFTR mRNA Splice Site (Class V) mutation or a residual function CFTR mutation in the CFTR gene (Section 16J of the Regulations). The Act imposes several obligations on the parties involved, particularly the sponsor of the therapeutic good. In this case, Vertex Pharmaceuticals Australia Pty Ltd is the sponsor of Ivacaftor (KALYDECO) and, as such, must ensure that the drug complies with all relevant requirements and regulations. This includes providing adequate information about the drug's safety, efficacy, and quality, as well as ensuring that it is manufactured, stored, and distributed in accordance with the Act and the Regulations. Furthermore, the sponsor must maintain records of all activities related to the drug, including clinical trials, manufacturing processes, and adverse event reporting, and must make these records available to the Therapeutic Goods Administration (TGA) upon request. Failure to comply with the requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in various civil and criminal consequences. For example, if a sponsor fails to provide accurate and complete information about a therapeutic good, or if they engage in fraudulent or misleading practices, they may be subject to fines, imprisonment, or both. In the case of Ivacaftor (KALYDECO), the maximum penalties for breaches of the Act and the Regulations may include fines of up to $1,100,000 for a corporation and/or imprisonment for up to 5 years for an individual. Additionally, the TGA has the authority to take enforcement actions, such as recalling non-compliant products or suspending or cancelling the registration of a therapeutic good. These penalties and consequences serve to ensure that the therapeutic goods available in Australia meet the highest standards of safety, efficacy, and quality, ultimately protecting the health and wellbeing of the Australian public.